{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(5)"],"submitter":["Ward T"],"funding":["Vifor Pharma"],"pubmed_abstract":["<h4>Background and objective</h4>Hyperkalaemia can be a life-threatening condition, particularly in patients with advanced chronic kidney disease with and without heart failure. Renin-angiotensin-aldosterone system inhibitor therapy offers cardiorenal protection in chronic kidney disease and heart failure; however, it may also cause hyperkalaemia subsequently resulting in down-titration or discontinuation of treatment. Hence, there is an unmet need for hyperkalaemia treatment in patients with chronic kidney disease with and without heart failure to enable renin-angiotensin-aldosterone system inhibitor use in this patient population. In this study, we develop a de novo disease progression and cost-effectiveness model to evaluate the clinical and economic outcomes associated with the use of "],"journal":["PharmacoEconomics - open"],"pagination":["757-771"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9440184"],"repository":["biostudies-literature"],"pubmed_title":["The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland."],"pmcid":["PMC9440184"],"pubmed_authors":["Quinn CM","Ward T","Lewis RD","de Arellano AR","Brown T","Kliess MK"],"additional_accession":[]},"is_claimable":false,"name":"The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland.","description":"<h4>Background and objective</h4>Hyperkalaemia can be a life-threatening condition, particularly in patients with advanced chronic kidney disease with and without heart failure. Renin-angiotensin-aldosterone system inhibitor therapy offers cardiorenal protection in chronic kidney disease and heart failure; however, it may also cause hyperkalaemia subsequently resulting in down-titration or discontinuation of treatment. Hence, there is an unmet need for hyperkalaemia treatment in patients with chronic kidney disease with and without heart failure to enable renin-angiotensin-aldosterone system inhibitor use in this patient population. In this study, we develop a de novo disease progression and cost-effectiveness model to evaluate the clinical and economic outcomes associated with the use of ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-19T10:42:04.592Z","creation":"2025-04-19T10:42:04.592Z"},"accession":"S-EPMC9440184","cross_references":{"pubmed":["35925491"],"doi":["10.1007/s41669-022-00357-z"]}}